Loading patent…
AssigneeCubist Pharmaceuticals, Inc.
InventorsThomas J. Kelleher, Jan-Ji Lai, Joseph P. DeCourcey, Paul D. Lynch, Maurizio Zenoni, Auro R. Tagliani
Estimating the term…
The invention discloses highly purified daptomycin and to pharmaceutical compositions comprising this compound. The invention discloses a method of purifying daptomycin comprising the sequential steps of anion exchange chromatography, hydrophobic interaction chromatography and anion exchange chromatography. The invention also discloses a method of purifying daptomycin by modified buffer enhanced anion exchange chromatography. The invention also discloses an improved method for producing daptomycin by fermentation of Streptomyces roseosporus. The invention also discloses high pressure liquid chromatography methods for analysis of daptomycin purity. The invention also discloses lipopeptide micelles and methods of making the micelles. The invention also discloses methods of using lipopeptide micelles for purifying lipopeptide antibiotics, such as daptomycin. The invention also discloses using lipopeptide micelles therapeutically.
1-10. (canceled)
A pharmaceutical composition comprising purified daptomycin greater than or about 93% purity relative to impurities 1-14 defined by peaks 1-14 shown in FIG. 12, the purified daptomycin being obtained by a process comprising the step of forming an aggregate comprising daptomycin, wherein the purified daptomycin is free of pyrogen, and wherein the composition optionally comprises a pharmaceutically acceptable carrier or excipient.
A pharmaceutical composition comprising purified daptomycin of greater than or about 93% purity relative to impurities 1-14 defined by peaks 1-14 shown in FIG. 12, the purified daptomycin being obtained by a process comprising the steps of forming a daptomycin aggregate, converting the daptomycin aggregate to monomers, and one or more steps selected from the group consisting of anion exchange chromatography and hydrophobic interaction chromatography, wherein the purified daptomycin is free of pyrogen, and wherein the composition optionally comprises a pharmaceutically acceptable carrier or excipient.
A pharmaceutical composition comprising purified daptomycin of greater than or about 93% purity relative to impurities 1-14 defined by peaks 1-14 shown in FIG. 12, wherein the purified daptomycin is free of pyrogen, and wherein the composition optionally comprises a pharmaceutically acceptable carrier or excipient.
Dependencies are inferred from the claim text.